In Vitro evaluation of T- cell Acute Lymphoblastic Leukemia cell line response to a combination of dual anticancer agent: SRJ23 and Hydroxyurea
T-cell acute lymphoblastic leukemia (T-ALL) is a hostile haematologic neoplasm caused by a malignant transformation of immature progenitors of T-cells. Due to the variable response to conventional chemotherapy regimens available to-date, a holistic chemotherapy combination drugs with greater pre...
| Main Authors: | , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2024
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/121122/ http://psasir.upm.edu.my/id/eprint/121122/1/121122.pdf |
| Summary: | T-cell acute lymphoblastic leukemia (T-ALL) is a hostile haematologic
neoplasm caused by a malignant transformation of immature
progenitors of T-cells. Due to the variable response to conventional
chemotherapy regimens available to-date, a holistic chemotherapy
combination drugs with greater precision to obtain the desired
results are worth studying. We aim to evaluate the inhibitory effect
of a readily available cyto-reducing agent, hydroxyurea (HU) with
SRJ23, on Jurkat cell line which are an immortalised of human T
lymphocyte cells to determine the efficacy in vitro. |
|---|